Immunome annual operating margin
2023
2024
2025
Immunome Operating Margin Growth & History (IMNM)
Immunome's operating margin was −3,228.83% for fiscal 2025.
View full Immunome company overviewImmunome annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −3,228.83% | +153.54 pp |
| 2024 | 2024-12-31 | −3,382.37% | −2601.02 pp |
| 2023 | 2023-12-31 | −781.35% | — |
Immunome quarterly operating margin
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2025 | 2025-06-30 | −1,157.61% | +534.82 pp |
| Q1 2025 | 2025-03-31 | −1,525.50% | +11331.55 pp |
| Q4 2024 | 2024-12-31 | −3,030.31% | −556.37 pp |
| Q3 2024 | 2024-09-30 | −1,736.15% | −1606.19 pp |
| Q2 2024 | 2024-06-30 | −1,692.43% | −1557.01 pp |
| Q1 2024 | 2024-03-31 | −12,857.05% | −12667.92 pp |
| Q4 2023 | 2023-12-31 | −2,473.94% | — |
| Q3 2023 | 2023-09-30 | −129.96% | — |
| Q2 2023 | 2023-06-30 | −135.42% | — |
| Q1 2023 | 2023-03-31 | −189.13% | — |
Immunome operating margin trends
Across the available reported history, Immunome's operating margin increased from −3,382.37% to −3,228.83%, a change of +153.54 percentage points. The latest reported quarter, Q2 2025, shows −1,157.61%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome filings at SEC.gov ↗